Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: A randomized controlled trial

Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: A randomized controlled trial

Summary. Background:A recombinant factor VIIa analog (NN1731; vatreptacog alfa [activated]) was developed to provide safe, rapid and sustained resolution of bleeds in patients with hemophilia and inhibitors. Patients/Methods:This global, prospective, randomized, double-blinded, active-controlled, do...

Full description

Saved in:
Bibliographic Details
Main Authors: Erich V. de Paula, Kaan Kavakli, Johnny Mahlangu, Yasmin Ayob, Steven R. Lentz, Massimo Morfini, László Nemes, Silva Z. Šalek, Midori Shima, Jerzy Windyga, Silke Ehrenforth, Ampaiwan Chuansumrit
Other Authors: Universidade Estadual de Campinas
Format: Article
Published: 2018
Subjects:
Medicine
Online Access:https://repository.li.mahidol.ac.th/handle/123456789/15121
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Mahidol University

Internet

https://repository.li.mahidol.ac.th/handle/123456789/15121

Similar Items